T Nozoe1, S Kohnoe, T Ezaki, A Kabashima, Y Maehara. 1. Department of Surgery, National Fukuoka Higashi Hospital, 1-1-1, Chidori, Koga, 811-3195, Japan. nozoe@fukuokae2.hosp.go.jp
Abstract
PURPOSE: The aim of the current study was to find out a clinicopathologic significance of CD44v6 over-expression in esophageal squamous cell carcinoma (ESCC), which has not been elucidated fully. METHODS: Immunohistochemical expression of CD44v6 was examined for 81 ESCCs. Correlation of CD44 over-expression with the clinicopathologic features were investigated. RESULTS: Thirty-eight ESCCs (46.9%) had over-expression of CD44v6. The proportions of the incidence of lymph node metastasis (P=0.039), lymphatic permeation (P=0.003), and blood vessel invasion (P=0.037) in ESCCs with over-expression of CD44v6 were significantly higher than those in ESCCs without over-expression of CD44v6. The stage of the tumor in ESCCs with over-expression of CD44v6 was significantly more advanced (P=0.045). Survival rates of patients with ESCC with over-expression of CD44v6 were significantly worse (P=0.0005). Moreover, CD44v6 over-expression (P=0.048) as well as blood vessel invasion (P=0.014) and stage of the tumor ( P=0.010) were factors independently associated with the unfavorable prognosis of the patients with ESCC. CONCLUSIONS: Over-expression of CD44v6 can be an indicator of the malignant potential of ESCC.
PURPOSE: The aim of the current study was to find out a clinicopathologic significance of CD44v6 over-expression in esophageal squamous cell carcinoma (ESCC), which has not been elucidated fully. METHODS: Immunohistochemical expression of CD44v6 was examined for 81 ESCCs. Correlation of CD44 over-expression with the clinicopathologic features were investigated. RESULTS: Thirty-eight ESCCs (46.9%) had over-expression of CD44v6. The proportions of the incidence of lymph node metastasis (P=0.039), lymphatic permeation (P=0.003), and blood vessel invasion (P=0.037) in ESCCs with over-expression of CD44v6 were significantly higher than those in ESCCs without over-expression of CD44v6. The stage of the tumor in ESCCs with over-expression of CD44v6 was significantly more advanced (P=0.045). Survival rates of patients with ESCC with over-expression of CD44v6 were significantly worse (P=0.0005). Moreover, CD44v6 over-expression (P=0.048) as well as blood vessel invasion (P=0.014) and stage of the tumor ( P=0.010) were factors independently associated with the unfavorable prognosis of the patients with ESCC. CONCLUSIONS: Over-expression of CD44v6 can be an indicator of the malignant potential of ESCC.
Authors: Lukas A Hefler; Nicole Concin; David Mincham; Jane Thompson; Nikkie B Swarte; Marion A van Eijkeren; Daisy M D S Sie-Go; Ian Hammond; Anthony J McCartney; Clemens B Tempfer; Paul Speiser Journal: Cancer Date: 2002-01-01 Impact factor: 6.860
Authors: Mahboubeh S Noori; Evan S Streator; Grady E Carlson; David S Drozek; Monica M Burdick; Douglas J Goetz Journal: Integr Biol (Camb) Date: 2018-12-19 Impact factor: 2.192
Authors: Gary D Stoner; Alan A Dombkowski; Rashmeet K Reen; Daniela Cukovic; Sridevi Salagrama; Li-Shu Wang; John F Lechner Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: Grégoire F Le Bras; Gillian L Allison; Nicole F Richards; Shazia S Ansari; M Kay Washington; Claudia D Andl Journal: PLoS One Date: 2011-11-01 Impact factor: 3.240
Authors: K A Whelan; P M Chandramouleeswaran; K Tanaka; M Natsuizaka; M Guha; S Srinivasan; D S Darling; Y Kita; S Natsugoe; J D Winkler; A J Klein-Szanto; R K Amaravadi; N G Avadhani; A K Rustgi; H Nakagawa Journal: Oncogene Date: 2017-04-17 Impact factor: 9.867